Rohan Ramakrishna, MD
(on 4th avenue)Doctors in Brooklyn, NY
Doctors
Rohan Ramakrishna, MD, is an award-winning neurosurgeon at NewYork-Presbyterian Medical Group Brooklyn and the chief of neurosurgery at NewYork-Presbyterian Brooklyn Methodist Hospital. He is an associate professor of neurological surgery at Weill Cornell Medicine, where he also directs the Brain Metastases Clinic. He specializes in the treatment of brain tumors and other central nervous system tumors. Dr. Ramakrishna treats patients with gliomas, metastatic disease, skull base lesions, and pituitary disorders. He employs advanced awake mapping, imaging techniques, and microsurgery to ensure maximal tumor removal and achieve the safest possible surgical outcomes. Furthermore, Dr. Ramakrishna works with a multi-disciplinary team to ensure that the best possible treatment strategies are offered to his patients. He sees patients at the Brain Tumor Center at New York Presbyterian/Weill Cornell Medical Center as part of the surgical neuro-oncology team.
Training
Dr. Ramakrishna received his Bachelor of Arts from the University of Pennsylvania, majoring in Biology and Philosophy, and was elected to the Phi Beta Kappa society upon graduation. He obtained his medical degree from the University of Pennsylvania. Dr. Ramakrishna completed his neurosurgery residency and served as chief resident at the University of Washington. He then went on to complete a fellowship in neurosurgical oncology at the MD Anderson Cancer Center in Houston, Texas.
Research
Dr. Ramakrishna’s research interests include novel drug delivery strategies to treat malignant brain and skull base tumors using advanced polymer and nanoparticle technology. Additionally, Dr. Ramakrishna is interested in developing new vaccine-based therapies for glioma and in helping to develop new clinical trials and outcome measures to advance the care of brain tumors. He has published and spoken extensively on these topics and has received multiple awards, including prestigious training and research grants from the NIH and the Fred Hutchinson Cancer Consortium.
